Start the conversation
If you've been studying the charts for Delcath Systems Inc. (Nasdaq: DCTH),you have to like what you see.
We most recently recommended the developer of an innovative treatment system for liver cancer back on Sept. 13. The closing price that day was $1.70.
After enduring a tough sell-off in the latter half of last month, Delcath's stock has been on fire of late. It was trading at $1.92 late yesterday - or about 13% above where we recommended it.
That's not an overly remarkable gain. But we like how the stock is acting.
This is premium content for Private Briefing subscribers only.